ONCT Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs...

Stats
Dzisiejszy wolumen	72.00
Średni wolumen	7 769.00
Kapitalizacja rynkowa	25.88M
EPS	$0 ( 2024-05-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.650
ATR14	$0.151 (1.73%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Wills Robert James	Buy	3 086	Common Stock
2024-03-28	Wills Robert James	Buy	6 914	Common Stock
2024-02-23	Hale David F	Buy	266	Common Stock
2024-02-23	Hale David F	Buy	714	Common Stock
2024-02-23	Wills Robert James	Sell	980	Common Stock

INSIDER POWER
19.18
Last 100 transactions
Buy: 5 802 851 \| Sell: 3 918 128

Oncternal Therapeutics Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oncternal Therapeutics Finanse

Annual	2023
Przychody:	$785 000
Zysk brutto:	$-28.97M (-3 690.19 %)
EPS:	$-13.43

FY	2023
Przychody:	$785 000
Zysk brutto:	$-28.97M (-3 690.19 %)
EPS:	$-13.43

FY	2022
Przychody:	$1.49M
Zysk brutto:	$1.31M (87.99 %)
EPS:	$-16.50

FY	2021
Przychody:	$4.32M
Zysk brutto:	$4.32M (100.00 %)
EPS:	$-0.640

Financial Reports:

No articles found.

Oncternal Therapeutics

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.